Compare moats

The filing's own words support a narrow moat. Auctions run 'at vast scale and at microsecond-level speeds,' revenue is earned only 'when our advertisers achieve their return on advertising spend targets,' and FY2025 adjusted EBITDA margin was 82.3%. What limits the width: clients 'are not required to enter into long-term agreements' and 'Substantially all of the Company's contracts with customers are cancelable at any time'; the solutions 'primarily operate in the mobile app ecosystem and specifically mobile gaming'; and distribution runs through 'the Apple App Store, the Google Play Store, and Meta' while AppLovin relies 'in part on IDFA.'

source: sec.gov

The FY2025 10-K describes a real but limited edge: after an automotive design win a competing product may not be able to displace the winner because it is 'very unlikely that a customer will change complex technology until a product model is revamped', and it claims technical barriers to entry and cites over 359 granted and over 102 pending patents. The same filing concedes intense, price-sensitive competition from larger rivals that may be able to offer competing functionality 'at lower cost or free of charge' within larger offerings, possible pricing pressure from OEMs, master service agreements customers can terminate on six months to one year of prior written notice, and, to date, substantial net losses and negative cash flows from operating activities. The stickiness is real, but it has not yet produced profits.

source: sec.gov

The FY2025 10-K publishes the expiry schedule of its own protection. The Patents table dates the basic U.S. product patent on Eliquis ($7,961 million of 2025 revenue) to 2027, the Prevnar family's Prevnar 13 ($6,494 million for the family) to 2026, the Vyndaqel family ($6,380 million) to 2026 with a 2028 extension only pending, Ibrance ($4,122 million) to 2027, Xtandi ($2,194 million) to 2027 and Xeljanz ($1,087 million) to 2026 - against Total revenues of $62,579 million. The filing then states it anticipates 'a significant reduction of revenue from patent-based or regulatory exclusivity expiries in 2026 through 2030 as several of our in-line products experience these expirations, with the rate of the reduction of revenues from patent-based or regulatory exclusivity expiries expected to significantly accelerate over the next few years', and puts the 2026 instalment at $1.5 billion. A protection whose end dates the issuer tabulates product by product, and whose revenue effect it forecasts as accelerating, is being consumed on a clock it has already disclosed.

source: sec.gov

Network effects, with a caveat. The 10-K states the loop: as more advertisers use the solutions 'we gain access to more data regarding users and user engagement,' 'further strengthening our scaled distribution,' and 'As our distribution grows, we gain better insights for Axon AI.' The mechanism is two-sided matching of advertiser demand to publisher supply, though much of the force comes from data-and-learning scale. It is not switching costs, since contracts are 'cancelable at any time,' nor intangibles or IP, since 'there can be no assurance that we will adequately protect our intellectual property or that it will provide any competitive advantage.'

source: sec.gov

The stickiest advantage in the 10-K is design-win lock-in: a product that did not win an OEM or Tier-1 design may not be able to displace the winner until the customer begins a new selection process, because the 10-K says customers are very unlikely to change complex technology until a product model is revamped. Private domains make SoundHound a long-term "partner" (the 10-K's quotation marks) because subscribing customers retain the ability to iterate and update their content on its platform. Patents are the weaker source: the filing warns that competitors 'may independently develop technologies that are substantially the same or superior' without infringing its rights.

source: sec.gov

The filing locates the protection in the patent estate, not anywhere else. The Patents and Other Intellectual Property Rights section tabulates 'the patent rights we consider most significant in relation to our business as a whole, together with the year in which the basic product patent expires', and states that once protection is lost 'we typically lose market exclusivity on these products, and generic and biosimilar pharmaceutical manufacturers generally produce identical or highly similar products and sell them for a lower price.' The Competition section names patents as the thing rivals attack: 'several of our competitors operate without large R&D expenses and make a regular practice of challenging our product patents before their expiration', and 'Generic pharmaceutical manufacturers pose one of the biggest competitive challenges to our branded small molecule products because they can market a competing version of our product after the expiration or loss of our patent protection.' No network, switching cost or cost-curve advantage is claimed anywhere in the section.

source: sec.gov

The filing discloses no share of any market, names 'Meta, Google, Amazon, and Unity Software' as competitors, and concedes rivals 'may have greater resources' and 'better technological or data analytics capabilities, or stronger brands or competitive positions in certain product segments.' Its one positional statement is parity language: 'We believe we compete favorably with respect to these factors.' Two unquantified points cut upward: Meta and Google are also clients, and MAX is called 'the preferred in-app bidding solution for many publishers worldwide.'

source: sec.gov

The 10-K calls SoundHound 'a global leader in conversational intelligence' with 'best-in-class speed and accuracy', but these are the company's own claims and it gives no share figure. Apart from the company's own positioning, such as its belief that some legacy vendors offer dated technologies, the 10-K's comparisons with rivals run against SoundHound: some current or potential competitors are large technology companies that have 'significantly greater financial, technical and marketing resources than SoundHound does', they may be able to respond more rapidly to new or emerging technologies, and its large competitors may have greater access to customer data, which the 10-K says provides them with a competitive advantage in developing new products and technologies.

source: sec.gov

The 2026 Pharma 50 (Drug Discovery & Development, published 31 March 2026, ranking pharmaceutical revenue only) places Pfizer third at $62.58 billion of FY2025 revenue inside a five-company band that runs from Johnson & Johnson's Innovative Medicine at $60.40 billion to Eli Lilly's $65.18 billion, with Merck & Co. at $65.01 billion and AbbVie at $61.16 billion in between - scale-equal to its nearest peers rather than ahead of them. The same piece attributes the top slot to Lilly's tirzepatide franchise, which it puts at $36.5 billion combined and says passed Keytruda as the world's best-selling drug; Pfizer's 10-K names no comparable single franchise, discloses no market-share position for any product, and concedes in Item 1A that 'some of our competitors may have competitive, technical or other advantages over us' and that it faces 'an increasing number of potential competitors worldwide, including from China, that have expanded R&D capabilities.'

source: sec.gov

Strong, with the mechanism shown. The 10-K states that 'Advertisers are charged dynamically based on their campaign goals , rather than a simple fixed price per impression or per action.' Growth composition is the evidence: FY2025 revenue +70% with 'the volume of installations increased 3% and net revenue per installation increased 72%'; H1 2026 +56% with per-installation revenue +75% against 'a decrease in the volume of installations of 10%.' Adjusted EBITDA margin was 82.3% in FY2025 and 84.2% in H1 2026, though payment is performance-contingent and contracts cancel at will.

source: sec.gov

The 10-K flags price sensitivity among customers, rival alternatives offered 'at significantly lower costs or free of charge', and the strong purchasing power of major OEMs, under which SoundHound may be expected to quote fixed prices or be forced to accept annual price-reduction commitments. GAAP gross margin, computed from the 10-K's revenue and cost of revenue, fell from 75.4% (FY2023) to 48.9% (FY2024) and 42.4% (FY2025). The company attributes both declines primarily to acquisitions: the FY2024 10-K cites Amelia and SYNQ3, including SYNQ3's lower-margin call-center agent business and amortization of acquired intangibles, and the FY2025 10-K cites Amelia and Interactions, including $14.1M and $0.8M of amortization of acquired intangibles. Neither passage attributes the decline to pricing. The Q2 2026 release (8-K filed 2026-08-05) reports GAAP gross margin up 6.1 points year over year to 45.1%, with non-GAAP gross margin flat at 58.4%.

source: sec.gov

Price is the lever the filing shows moving against it. CMS selected Eliquis - which the 10-K says 'accounted for 13% of Total revenues in 2025' - for the Medicare Drug Price Negotiation Program, and 'its government-set Maximum Fair Price became effective January 1, 2026', with Ibrance and Xtandi following in 2027 and Xeljanz in 2028. In September 2025 Pfizer 'voluntarily agreed' with the U.S. administration to make certain U.S. prices 'more comparable to those in other developed countries' and to sell through the TrumpRx.gov platform 'at significant discounts to current retail prices'. Gross-to-net product revenue deductions rose to $36,374 million in 2025 from $30,048 million in 2023 while Total revenues fell to $62,579 million, and the IRA Medicare Part D Redesign alone 'negatively impacted our 2025 revenues by approximately $1 billion'. Lower U.S. net price is named as a drag on Vyndaqel, Ibrance, Xeljanz, Nurtec ODT and Lorbrena; every 2025 growth line the filing explains is attributed to demand, patient share or launch uptake, none to price. Cost of sales at 25.7% of revenues shows the manufactured margin is intact - what is not intact is the ability to set the price.

source: sec.gov

Demand-side AI ad platform: it monetizes third-party mobile-game publishers' inventory and sells outcomes to advertisers, so it sits downstream of Apple/Google app distribution and Apple's IDFA identifier layer and upstream of publisher monetization. Meta and Google are simultaneously named competitors and disclosed clients. Single reportable segment after the June 2025 Apps divestiture.

Voice and agentic AI layer that OEMs, restaurants and enterprises embed under their own brand. Per the 10-K it combines its domains with third-party LLMs such as OpenAI's ChatGPT and runs on hosting facilities and third-party public clouds.

Demand side of the AI chain, not a supplier into it. The 10-K lists 'Scale AI across our business' as one of four 2026 key priorities and describes 'expanding automation, data-driven decision making, and enterprise AI solutions', crediting 'enhanced digital enablement, including automation and AI' for part of the savings in its cost-realignment and R&D-simplification programs. It describes no AI model, tool or platform that Pfizer sells.

• Adjust Unknown · Moderate source: sec.gov
• AppLovin Ads (Axon Ads Manager) Unknown · Moderate source: sec.gov
• MAX Unknown · Moderate source: sec.gov
• Wurl Niche · Low source: sec.gov

• Houndify Voice AI platform (automotive, TV, IoT) Unknown · Moderate source: sec.gov
• OASYS enterprise agentic AI platform Unknown · Low source: sec.gov
• Smart Ordering and Smart Answering (restaurant voice AI) Unknown · Low source: sec.gov
• SoundHound Chat AI (generative voice assistant) Unknown · Low source: sec.gov

• Comirnaty Unknown · Deep source: sec.gov
• Eliquis Unknown · Low source: sec.gov
• Ibrance Unknown · Low source: sec.gov
• Padcev Unknown · Moderate source: sec.gov
• Prevnar family Unknown · Moderate source: sec.gov
• Vyndaqel family Unknown · Low source: sec.gov

Editorial prior, not backtested.

see exactly how it voted →

Editorial prior, not backtested.

see exactly how it voted →

Editorial prior, not backtested.

see exactly how it voted →